Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Plasma cell 1Lymphoid 1

Conditions

Vomiting 16Nausea 13Neoplasms 5Breast Neoplasms 3Rectal Neoplasms 2Hematologic Neoplasms 2Colorectal Neoplasms 2Colonic Neoplasms 2Breast Neoplasms, Male 2Weight Loss 1Stomach Neoplasms 1Squamous Cell Carcinoma of Head and Neck 1Sarcoma 1Pancreatic Neoplasms 1Nausea With Vomiting Chemotherapy-Induced 1Multiple Myeloma 1Melanoma 1Lymphoma 1Liver Neoplasms 1Leukemia, Myeloid, Acute 1Leukemia 1Inflammatory Breast Neoplasms 1Hematologic Diseases 1Glioma 1Gallbladder Neoplasms 1Carcinoma, Hepatocellular 1Brain Neoplasms 1Bile Duct Neoplasms 1Appendiceal Neoplasms 1Anus Neoplasms 1

Interventions

Rituximab 173Cyclophosphamide 156Vincristine 72fludarabine phosphate 71Etoposide 68Doxorubicin 68Prednisone 66Filgrastim 58Methotrexate 52Cytarabine 51fludarabine 49Melphalan 48Busulfan 47Tacrolimus 41Whole-Body Irradiation 39Mycophenolic Acid 39Granulocyte Colony-Stimulating Factor 37Antilymphocyte Serum 31Peripheral Blood Stem Cell Transplantation 30Radiotherapy 27Lenalidomide 25Dexamethasone 25Carmustine 23Stem Cell Transplantation 22Cyclosporine 22Bortezomib 22Gemcitabine 20Bendamustine Hydrochloride 20ibritumomab tiuxetan 19Alemtuzumab 19

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Has results × Lymphoma × Palonosetron × Clear all
NCT00600353 2017-03-09

Multi-day Doses in Prevention of Nausea and Emesis

University of Kansas Medical Center

Phase 2 Completed
20 enrolled 8 charts
LymphoidPlasma cell

Lymphoma, Multiple Myeloma, Nausea, Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡